Hostname: page-component-cd9895bd7-jkksz Total loading time: 0 Render date: 2024-12-22T23:55:11.189Z Has data issue: false hasContentIssue false
  • English
  • Français

Typical and atypical antipsychotics in bipolar disorder

Published online by Cambridge University Press:  18 September 2015

R.W. Licht
R.W. Licht*
Affiliation:
Aarhus University Psychiatric Hospital, Risskov, Denmark
*
Mood Disorders Research Unit, Aarhus University Psychiatric Hospital, DK-8240 Risskov, DenmarkTel 45-77892470, Fax 45-77892479, E-mail [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Background: In clinical practice, typical antipsychotics are widely used in the treatment of bipolar disorder, albeit in treatment guidelines often considered as adjunctive agents only. Recently, focus has shifted towards the use of atypical antipsychotics. This paper reviews the advantages and disadvantages associated with the use of antipsychotics in bipolar disorder.

Methods: Randomised controlled trials (RCTs) were selected for review. A few review articles were also cited.

Results: Typical antipsychotics, at least some of them, are powerful antimanics, beneficial for severe agitation in particular. However, in the long term treatment, typical antipsychics may precipitate depression. Among the atypical antipsychotics, both risperidone and olanzapine are clearly antimanic alternatives, although olanzapine is the best studied. Clozapine seems to be useful when other treatments fail to work.

Conclusions: Antipsychotics are beneficial for some clinical presentations of mania. To minimize side effets, atypical agents should be preferred before typical agents, unless parenteral administration is needed. Despite the lack of RCTs, antipsychotics also seem to be useful as adjunctive agents in the treatment of psychotic bipolar depression. For the long term treatment of bipolar disorder, typical antipsychotics should be used only under certain circumstances. The place of atypical antipsychotics in the long term treatment of bipolar disorder remains to be studied.

Keywords

bipolar disordermaniaantipsychotic agentstreatmentreview
Type
Articles
Information
Acta Neuropsychiatrica , Volume 12 , Issue 3 , September 2000 , pp. 115 - 119
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Licht, RW, Gouliaev, G. Vestergaard, P. Dybbro, J. Lund, H. Merinder, L. Treatment of manic episodes in Scandinavia: the use of neuroleptic drugs in a clinical routine setting. J Affect Disord 1994; 32:179–185.CrossRefGoogle ScholarPubMed
2.Chou, JCY. Zivkov, M, Voldby, H, Creelman, WL. Alterman, D. Dahl, SG. Neuroleptics in acute mania: a pharmacoepidemiological study. Ann Pharmacother 1996:30:1396–1398.CrossRefGoogle Scholar
3.Licht, RW. Drug treatment of mania: a critical review. Acta Psychiatr Scand 1998:97:387–397.CrossRefGoogle ScholarPubMed
4.Goodwin, GM. Recurrence of mania after lithium withdrawal. Implications for the use of lithium in the treatment of bipolar affective disorder. Br J Psychiatry 1994:164:149–152.CrossRefGoogle ScholarPubMed
5.Keck, PE. Jr., Licht, RW. Antipsychotic medications in the treatment of mood disorders. In: Buckley, PF. Waddington, JL (eds.). Schizophrenia and Mood Disorders. The Drug Therapies in Clinical Practice. Oxford. Butterworth-Heinemann. 2000, pp 199–211.Google Scholar
6.Rifkin, A. Doddi, S. Karajgi, B, Borenstcin, M. Munne, R. Dosage of haloperidol for mania. Br J Psychiatry 1994;165:113–116.CrossRefGoogle ScholarPubMed
7.Licht, RW. Experience with benzodiazepines in the treatment of mania. In: Modigh, K. Robak, OH. Vestergaard, P (eds). Anticonvulsants in Psychiatry. Petersfield, Wrightson Biomedical Publishing Ltd, 1994. pp 37–55.Google Scholar
8.Calabrese, JR. Kimmel, SE. Woyshville, MJet al.Clozapine for treatment-refractory mania. Am J Psychiatry 1996;153:759–764.Google ScholarPubMed
9.Tohen, M. Zarate, CA. Centorrino, F. Hegarty, JI, Froeschl, M. Zarate, SB. Risperidone in the treatment of mania. J Clin Psychiatry 1996:57:249–253.Google ScholarPubMed
10.Segal, J, Berk, M, Brook, S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol 1998:21:176–180.Google Scholar
11.Tohen, M, Sanger, TM, McElroy, SLet al.Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 1999:156:702–709.CrossRefGoogle ScholarPubMed
12.Bowden, CL, Bruggcr, AM, Swann, ACet al.Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994:271:918–924.CrossRefGoogle ScholarPubMed
13.Berk, M, Ichim, L, Brook, S. Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. Int Clin Psychopharmacol 1999;14:339–343.CrossRefGoogle Scholar
14.Bocchetta, A, Bernardi, F, Burrai, C, Pedditzi, M. Del Zompo, M. A double-blind study of L-sulpiride versus amitriptyline in lithium-maintained bipolar depressives. Acta Psychiatr Scand 1993:88:434–439.CrossRefGoogle ScholarPubMed
15.Licht, RW, Olesen, OV. Friis, P. Laustsen, T. Olanzapine serum concentrations lowered by concomitant treatment with carbamazepine. J Clin Psychopharmacol 2000; 20:110–112.CrossRefGoogle ScholarPubMed